| Product Code: ETC6739563 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, 2021 & 2031F |
3.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Industry Life Cycle |
3.4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Porter's Five Forces |
3.5 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.7 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.8 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Diagnosis, 2021 & 2031F |
3.9 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.10 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of COPD in China due to factors like air pollution, smoking, and aging population |
4.2.2 Rising awareness about COPD diagnosis and treatment options among healthcare providers and patients |
4.2.3 Government initiatives to improve healthcare infrastructure and access to COPD treatment in China |
4.3 Market Restraints |
4.3.1 High cost associated with COPD medications and treatments, limiting affordability for a significant portion of the population |
4.3.2 Stringent regulatory requirements for drug approval and market entry in China, leading to delays in product launches |
4.3.3 Limited availability of advanced COPD treatment options in certain regions of China |
5 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Trends |
6 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Types |
6.1 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Phosphodiestrase-4 Inhibitors, 2021- 2031F |
6.1.4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Long-Acting Bronchodilators, 2021- 2031F |
6.1.5 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Short-Acting Bronchodilators, 2021- 2031F |
6.1.6 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Methylxanthines, 2021- 2031F |
6.1.7 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Product Type |
6.2.1 Overview and Analysis |
6.2.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Inhalers, 2021- 2031F |
6.2.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Nebulizers, 2021- 2031F |
6.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Type |
6.3.1 Overview and Analysis |
6.3.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Chronic Bronchitis, 2021- 2031F |
6.3.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Emphysema, 2021- 2031F |
6.4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Diagnosis |
6.4.1 Overview and Analysis |
6.4.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Pirometry, 2021- 2031F |
6.4.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Diagnostic Tests, 2021- 2031F |
6.4.4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.5 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By Treatment |
6.5.1 Overview and Analysis |
6.5.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Oxygen Therapy, 2021- 2031F |
6.5.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Lung Transplant, 2021- 2031F |
6.5.4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Drug Therapy, 2021- 2031F |
6.5.5 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Vaccination, 2021- 2031F |
6.5.6 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Surgery, 2021- 2031F |
6.5.7 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.6 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market, By End User |
6.6.1 Overview and Analysis |
6.6.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Hospitals & Clinics, 2021- 2031F |
6.6.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Home Care Settings, 2021- 2031F |
6.6.4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenues & Volume, By Others, 2021- 2031F |
7 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Import-Export Trade Statistics |
7.1 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Export to Major Countries |
7.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Imports from Major Countries |
8 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Key Performance Indicators |
8.1 Number of COPD patients diagnosed and under treatment in China |
8.2 Percentage of healthcare facilities equipped to diagnose and treat COPD effectively |
8.3 Government healthcare expenditure allocated towards COPD management and treatment |
8.4 Rate of adoption of new COPD treatment guidelines by healthcare providers |
9 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Opportunity Assessment |
9.1 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.3 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.4 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Diagnosis, 2021 & 2031F |
9.5 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.6 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Opportunity Assessment, By End User, 2021 & 2031F |
10 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market - Competitive Landscape |
10.1 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Revenue Share, By Companies, 2024 |
10.2 China Chronic Obstructive Pulmonary Disease (COPD) Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here